|
[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
|
[2]MARION PL, WINTERS MA, SALAZAR FH, et al.Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Antimicrob[J].Agents Chemother, 2002, 46 (1) :82-88.
|
|
[3]WOLTERS LM, HANSEN BE, NIESTERS HG, et al.Viral dynamics in chronic hepatitis B patients during lamivudine therapy[J].Liver, 2002, 22 (2) :121-126.
|
|
[4]LUO KX.Hepatitis B basic biology and clinical science[M].3rd ed.Beijing:People's Medical Publishing House, 2006:54-58. (in Chinese) 骆抗先.乙型肝炎基础和临床[M].3版.北京:人民卫生出版社, 2006:54-58.
|
|
[5]KOCK J, THEILMANN L, GALLE P, et al.Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J].Hepatology, 1996, 23 (3) :405-413.
|
|
[6]TANAKA E, ROKUHARA A, MATSUMOTO A, et al.Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy[J].Gastroenterol, 2006, 41 (8) :785-790.
|
|
[7]SU Q, WANG SF, CHANG TE, et al.Circulating hepatitis B virus nucleic acids in chronic infection:represantation of differently polyadenylated viral transcripts during progression to nonreplicative stages[J].Clin Cancer, 2001, 7 (7) :2005-2015.
|
|
[8]Chinese Journal of Hepatology, Journal of Clinical Hepatology, Chinese Hepatology.Potential clinical significance of serum HBV RNAvirus-like particles[J].J Clin Hepatol, 2016, 32 (9) :1635-1636. (in Chinese) 中华肝脏病杂志, 临床肝胆病杂志, 《肝脏》杂志.HBV RNA病毒样颗粒的潜在临床意义[J].临床肝胆病杂志, 2016, 32 (9) :1635-1636.
|
|
[9]HUI CK, CHEUNG WW, ZHANG HY, et al.Kinetics and risk of denovo hepatitis B infection in HBs Ag-negative patients undergoing cytotoxic chemotherapy[J].Gastroenterology, 2006, 131 (1) :59-68.
|
|
[10]LU FM, REN H, KUMAR GR, et al.Serum hepatitis B virus RNAis encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol, 2016, 65 (4) :700-710.
|
|
[11]WANG J, DU M, HUANG H, et al.Reply to:“Serum HBVpgRNA as a clinical marker for ccc DNA activity”[J].J Hepatol, 2016, 66 (2) :462-463.
|
|
[12]GIERSCH K, All WEISS L, VOLZ T, et al.Serum HBV pgRNA as a clinical marker for ccc DNA activity[J].J Hepatol, 2017, 66 (2) :460-462.
|
|
[13]LU FM, WANG J, NIU JQ, et al.Serum HBV RNA can reflect the activity of intrahepatic ccc DNA[C].26th Annual Conference of APASL.Shanghai, 2017.
|
|
[14]TSUGE M, MURAKAMI E, IMAMURA M, et al.Serum HBVRNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J].Gastroenterol, 2013, 48 (10) :1188-1204.
|
|
[15]BARTENS A, HOFMANN J, EDELMANN A, et al.Serum hepatitis Bvirus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J].Hepatology, 2015, 61 (1) :66-76.
|
|
[16]BERG T, WACKER J, BREHM M, et al.HBV RNA and HBVcore-related antigen (HBcr Ag) are early serum markers for HBe Ag seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF) [C].67th annual meeting of the American Association for the Study of Liver Diseases.Boston, 2016.
|
|
[17]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.
|
|
[18]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
|
|
[19]ZHAO YN, LI H.Advances in research on anti HBV target[J].Int J Virol, 2017, 24 (3) :197-200. (in Chinese) 赵亚楠, 李红.抗乙型肝炎病毒靶点研究进展[J].国际病毒学杂志, 2017, 24 (3) :197-200.
|
|
[20]SCHALM SW, HEATHCOTE J, CIANCIARA J, et al.Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomized trial[J].Gut, 2000, 46 (4) :562-568.
|
|
[21]SARIN SK, KUMAR M, KUMAR R, et al.Higher efficacy of sequential therapy with interferon-alpha and Lamivudine combination compared to Lamivudine monotherapy in HBe Ag positive chronic hepatitis B patients[J].Am J Gastroenterol, 2005, 100 (11) :2463-2471.
|
|
[22]SARIN SK, SOOD A, KUMAR M, et al.Effect of lowering HBVDNA levels by initial antiviral therapy before adding immunodulator on treatment of chronic hepatitis B[J].Am J Gastroenterol, 2007, 102 (1) :96-104.
|
|
[23]CHAYAMA K, HUANG YW, HATAKEYAMA T, et al.Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B[J].Antivir Ther, 2010, 15 (2) :177-184.
|
|
[24]DIENSTAG JL.Hepatitis B virus infection[J].N Engl J Med, 2008, 359 (14) :1486-1500.
|
|
[25]WIELAND SF, GUIDOTTI LG, CHISARI FV, et al.Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice[J].J Virol, 2000, 74 (9) :4165-4173.
|
|
[26]DOONG SL, TSAI CH, SCHINAZI RF, et al.Inhibition of the replication of hepatitis B virus in vitro by 2'3'-dideoxy-3'-thiacytidine and related analogues[J].Proc Natl Acad Sci USA, 1991, 88 (19) :8495-8499.
|
|
[27]TAKAHASHI S, TSUGE M, HUANG YW, et al.On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy[J].Antiviral Therapy, 2015, 20 (4) :369-375.
|
|
[28]JANSEN L, KOOTSTRA NA, van DORTKA, et al.Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues[J].Infect Dis, 2016, 213 (2) :224-232.
|
|
[29]HAYASHI Y, BAI F, FUKUMOTO T, et al.Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma[J].Int Hepatol, 2013, 2013:849290.
|
|
[30]HIRAGA N, HATAKEYAMA T, NOGUCHI C, et al.Serum HBV RNAis a predictor of early emergence of the YMDD mutant in patients treated with Lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.
|
|
[31]REIJNDERS JG, PERQUIN MJ, ZHANG N, et al.Nucleos (t) ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology, 2010, 139 (2) :491-498.
|
|
[32]CHI H, HANSEN BE, YIM C, et al.Reduced risk of relapse after long-term nucleos (t) ide analogue consolidation therapy for chronic hepatitis B[J].Aliment Pharmacol Ther, 2015, 41 (9) :867-876.
|
|
[33]RYU SH, CHUNG YH, CHOI MH, et al.Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBe Ag loss:a prospective study[J].J Hepatol, 2003, 39 (4) :614-619.
|
|
[34]WANG Y, THONGSAWAT S, GANE EJ, et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J].J Viral Hepat, 2013, 20 (4) :e37-e46.
|
|
[35] LU FM, WANG J, REN H, et al.The potential use of serum HBVRNA to guide the functional cure of chronic hepatitis B[J].Chin JHepatol, 2017, 25 (2) :105-110. (in Chinese) 鲁凤民, 王杰, 任红, 等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志, 2017, 25 (2) :105-110.
|
|
[36]SEEGERC, MASON WS.Hepatitis B virus biology[J].Microbiol Mol Biol Rev, 2000, 64 (1) :51-68.
|
DownLoad: